Low-dose recombinant activated factor VII in massively transfused trauma patients with coagulopathy.
Bauzá
Graciela
G
Hirsch
Erwin
E
Burke
Peter
P
Quillen
Karen
K
D000293:Adolescent; D000328:Adult; D000368:Aged; D001778:Blood Coagulation Disorders / Q000150:complications / Q000628:therapy*; D016913:Blood Component Transfusion / Q000009:adverse effects / Q000379:methods*; D004305:Dose-Response Relationship, Drug; D005167:Factor VII / Q000008:administration & dosage / Q000627:therapeutic use*; D015942:Factor VIIa / Q000008:administration & dosage / Q000627:therapeutic use*; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D019934:International Normalized Ratio; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013997:Time Factors; D016896:Treatment Outcome; D014947:Wounds and Injuries / Q000150:complications / Q000628:therapy
D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa